Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for ...
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...
Evidence is mounting that food packaging and plastic tableware contain toxic chemicals absorbed by humans, a public health ...
Update on FDA's Applied Therapeutics, Inc. decision to remove advisory panel for govorestat review in treating galactosemia.
The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks ...
The U.S. Food and Drug Administration (FDA) recently issued revised guidance on the control and mitigation of nitrosamine impurities in human drugs. The guidance provides a comprehensive roadmap for ...